Zack's likes Rosetta Genomics

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Zacks Small Cap Research initiates coverage on Rosetta Genomics (ROSG) with an Outperform rating.

Analysts like the company's microRNA platform and establish a price target of $10.

Shares currently exchange hands at $5.30.